Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase NA 1Phase 2 1

Status

Completed 3Unknown 1Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Lambert-Eaton Myasthenic Syndrome 2Myasthenia Gravis 1

Interventions

Cyclophosphamide 299Cisplatin 298Paclitaxel 257Radiotherapy 255Fluorouracil 234Carboplatin 234Docetaxel 230Doxorubicin 216Dexamethasone 166Gemcitabine 156Vincristine 147Etoposide 136Leucovorin 133Capecitabine 129Bevacizumab 129Prednisone 125Rituximab 118Methotrexate 118Cytarabine 110Filgrastim 99Trastuzumab 97Oxaliplatin 96pembrolizumab 83Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Daunorubicin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Completed × Amifampridine × Clear all
NCT03304054 2024-03-12

Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG

Catalyst Pharmaceuticals, Inc.

Phase 3 Completed
93 enrolled 11 charts

Myasthenia Gravis

NCT02970162 2018-12-24

Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)

Catalyst Pharmaceuticals, Inc.

Phase 3 Completed
26 enrolled 10 charts

Lambert-Eaton Myasthenic Syndrome

NCT01377922 2018-01-04

A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

Catalyst Pharmaceuticals, Inc.

Phase 3 Completed
38 enrolled 12 charts

Lambert-Eaton Myasthenic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡